Recent Updates
Recently added Catalysts
PYPD Positive Sentiment

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

Key Takeaway: PolyPid Ltd. has announced its participation in the Barclays 26th Annual Global Healthcare Conference, scheduled for March 12-14, 2024, in Miami Beach, FL. The company's management will engage in a fireside chat and hold one-on-one meetings with investors during the event. PolyPid is focused on improving surgical outcomes through its proprietary PLEX technology and is currently advancing its lead product candidate, D-PLEX100, in a Phase 3 clinical trial aimed at preventing surgical site infections.
Price reaction · baseline $5.475 (2024-02-27 close) · hit after-hours · clean, no other PYPD news in the window
day 0 close
+8.7%
day 1
-2.1%
day 3
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference enhances visibility.
  • Opportunity for one-on-one meetings with investors can boost funding.
  • PolyPid's innovative approach aims to improve surgical outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+50%
120-day peak, hindsight
Typical move
4.8%
average across 4 past catalysts
Lead asset
D-PLEX
Phase 3 · Surgical Site Infection

Full Press Release Details

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.
Barclays 26th Annual Global Healthcare Conference Fireside Chat
Date: Thursday, March 14, 2024
Time: 7:30 – 7:55 AM ET
The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Barclays representative.
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

Frequently Asked Questions

What is the date of the Barclays 26th Annual Global Healthcare Conference?

The conference will take place from March 12 to 14, 2024.

What is PolyPid's main focus as a biopharma company?

PolyPid aims to improve surgical outcomes through innovative therapeutics.

What technology does PolyPid use for drug delivery?

PolyPid utilizes PLEX technology for controlled, prolonged-release therapeutics.

What is the focus of PolyPid's lead product candidate, D-PLEX100?

D-PLEX100 targets the prevention of abdominal colorectal surgical site infections.

Last updated: Feb 28, 2024